Date | Compound | Laboratory | Indication | Type of Information |
---|---|---|---|---|
2013-05-01 | mexiletine hydrochloride | Prof Michael Hanna (UK) | non-dystrophic myotonia | Granting of the orphan status in the EU |
2013-05-01 | autologous CD34+ cells transduced with a lentiviral vector containing the human ADAgene | Prof. Bobby Gaspar (UK) | adenosine deaminase-deficient severe combined immunodeficiency | |
2018-01-04 | maribavir | Viropharma (USA), now Shire (UK - USA) |
|
Granting of the Breakthrough Therapy status |
2013-06-07 | N-methyl-4-({4-[({3-methyl(methylsulfonyl)aminopyrazin-2-yl}methyl)amino]-5-(trifluoromethyl)pyrimidin-2-yl}amino)benzamide hydrochloride | TMC Pharma Services (UK) | malignant mesothelioma |
Granting of the orphan status in the EU |
2013-05-01 | recombinant human CXCL8 mutant | ProtAffin Biotechnologie (Austria) | cystic fibrosis | |
2013-05-01 | recombinant human transglutaminase 1 encapsulated into liposomes | Westfälische WilhelmsUniversität Münster (Germany) | transglutaminase-1-deficient autosomal recessive congenital ichthyosis | |
2013-05-02 | tocilizumab | Roche (Switzerland) | polyarticular juvenile idiopathic arthritis (PJIA) | Granting of a Market Authorisation in the EU |
2013-05-02 | fixed-dose combination of a carbonic anhydrase inhibitor (Brinzolamide 1.0%) and an alpha 2 adrenergic receptor agonist (Brimonidine Tartrate 0.2%) | Alcon, a division of Novartis (Switzerland) | reduction of elevated intraocular pressure (IOP) in patients with primary open-angle glaucoma or ocular hypertension |
Granting of a Market Authorisation in the EU |
2013-05-02 | KB001A | Sanofi Pasteur (France) KaloBios Pharmaceuticals (USA - CA) | protection against bacterial pneumonia caused by Pseudomonas aeruginosa (Pa) in mechanically-ventilated patients |
Granting of a Fast Track status |
2016-06-29 | tacrolimus | Veloxis Pharmaceuticals (Denmark) | prevention of organ rejection in kidney transplant patients | Product launch |
2016-03-09 | lenvatinib | Eisai (Japan) |
|
Reimbursement |
2013-05-07 | 4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-quinoline-6- carboxamide monohydrate | Eli Lilly (USA) | glioma | |
2013-05-07 | (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one | Voisin Consulting (France) | chronic lymphocytic leukaemia/small lymphocytic lymphoma | |
2013-05-07 | 2-hydroxypropyl-?-cyclodextrin | International Niemann-Pick Disease Alliance (INPDA) | Niemann-Pick disease, type C | |
2013-05-07 | R,S-O-(3-piperidino-2-hydroxy-1-propyl)-nicotinic acid amidoxime dihydrochloride | N-GENE Kutatási és Fejlesztési Kft (Hungary) | Duchenne muscular dystrophy |
Granting of the orphan status in the EU |
2013-05-07 | TM-400 | TikoMed (Sweden) | mobilization of stem cells prior to stem cell transplantation treatment | |
2013-09-03 | canakinumab | Novartis (Switzerland) | systemic juvenile idiopathic arthritis (SJIA) |
Granting of a Market Authorisation in the EU |
2013-05-20 | pexastimogene devacirepvec | Jennerex (USA) | hepatocellular carcinoma | |
2013-05-22 | pixantrone | Cell Therapeutics (USA) | non-Hodgkin’s B-cell lymphoma |
Reimbursement |
2017-11-02 | isavuconazonium sulfate | Basilea Pharmaceutica (Switzerland) Astellas Pharma (Japan) | invasive aspergillosis | Product launch |
© 2024 Biopharmanalyses - Powered by Samacom+